Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Study of SNX-5422 in TP53 Null Cancers

ClinicalTrials.gov ID: NCT02612285

Public ClinicalTrials.gov record NCT02612285. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 8:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Single Arm Study of SNX-5422 in Subjects With TP53 Null Cancers

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

SNX-5422 is a pro-drug of SNX-2112, a potent, highly selective, small-molecule inhibitor of the molecular chaperone heat shock protein 90 (Hsp90). Initial in vitro evidence supports that SNX-5422 may be active against TP53 null tumors irrespective of tumor type .

Study identification

NCT ID
NCT02612285
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Esanex Inc.
Industry
Enrollment
1 participant

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 29, 2016
Primary completion
Sep 30, 2016
Completion
Sep 30, 2016
Last update posted
Nov 13, 2018

2016

United States locations

U.S. sites
5
U.S. states
4
U.S. cities
5
Facility City State ZIP Site status
HonorHealth Research Institute Scottsdale Arizona 85258
Augusta University Augusta Georgia 30912
Karmanos Cancer Institute Detroit Michigan 48201
Gabrail Cancer Center Research Canton Ohio 44718
Wexner Medical Center, Ohio State University Columbus Ohio 43210

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02612285, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 13, 2018 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02612285 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →